MedTrace Logo

Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

NCT07255781 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-02-23

No results posted yet for this study

Summary

The goal of this research study is to better understand if there is an association between non-alcoholic fatty liver disease (NAFLD) and active psoriatic disease (PD), and to assess the effect of Guselkumab (a medication approved by the FDA instead of the standard of care to treat PD), for NAFLD patients who receive Guselkumab for their PD.

Conditions

  • Psoriasis (PsO)
  • PsA (Psoriatic Arthritis)
  • NAFLD (Nonalcoholic Fatty Liver Disease)

Interventions

DRUG

Guselkumab Prefilled Syringe [Tremfya]

This trial aims to recruit patients who have psoriatic disease, have evidence of fatty liver disease, and have a BMI over 25, who are planning to start Guselkumab(Tremfya) as recommended by their primary rheumatologist or dermatologist

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2025-11-30
Completion
2025-11-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07255781 on ClinicalTrials.gov